HENRI A. TERMEER - Corporate Board Profile

abrdn Life Sciences Investors

Filing Date	Source Excerpt
2001-05-15	HENRI A. TERMEER** (55), Chairman (since 1988), Chief Executive Officer (since 1985) and President (since 1983) of Genzyme Corporation (human healthcare products); Director (since 1987) of ABIOMED, Inc.; Director (since 1992) of AutoImmune, Inc.; Director (since 1993) of Genzyme Transgenics; Director (since 1996) of Diacrin, Inc.; and Trustee (since 1989) of HQH and (since 1992) of HQL.
2002-05-17	HENRI A. TERMEER** (56), Chairman (since 1988), Chief Executive Officer (since 1985) and President (since 1983) of Genzyme Corporation (human healthcare products); Director (since 1987) of ABIOMED, Inc.; Director (since 1992) of AutoImmune, Inc.; Director (since 1993) of Genzyme Transgenics; Director (since 1996) of Diacrin, Inc.; and Trustee (since 1989) of HQH and (since 1992) of HQL.
2004-05-24	HENRI A. TERMEER^ (58), GENZYME CORPORATION, 500 KENDALL STREET, CAMBRIDGE, MA 02139 Trustee of HQH (since 1989) and of HQL (since 1992), Chairman (since 1988), Chief Executive Officer (since 1985), and President (since 1983) of Genzyme Corporation (human healthcare products); Director (since 1987) of ABIOMED, Inc. * Trustee considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act"), through position or affiliation with Hambrecht & Quist Capital Management LLC (the "Adviser"). ** Member of each Fund's Audit Committee. # Member of each Fund's Valuation Committee. ^ Member of each Fund's Corporate Governance and Nominating Committee. + Member of each Fund's Qualified Legal Compliance Committee. The members of each Fund's Nominating and Governance Committee are Messrs. Lewin and Termeer and Dr. Mack. Mr. Lewin is the Chairman of each Fund's Nominating and Governance Committee. For the fiscal year ended September 30, 2003, the annual fee was $15,000. Trustees of each Fund are also paid $1,000 for each Board and Committee meeting attended in person and $500 for each Board and Committee meeting attended by telephone. The Chairman of the Board of Trustees of each Fund receives an additional annual fee of $2,500, the Chairman of each Committee receives an additional annual fee of $1,500 and each Committee member receives an additional annual fee of $500. Independent Trustees as a group received $136,980 from HQH and $134,714 from HQL for fees and reimbursed expenses. The following table sets forth information regarding compensation of Trustees by the Funds for the fiscal year ended September 30, 2003, but does not include expenses. Henri A. Termeer $19,500 from each Fund, total $39,000.
2005-05-10	HENRI A. TERMEER^~ (59), GENZYME CORPORATION, 500 KENDALL STREET, CAMBRIDGE, MA 02139 Trustee of HQH (since 1989) and of HQL (since 1992); Chairman (since 1988), Chief Executive Officer (since 1985), and President (since 1983) of Genzyme Corporation (human healthcare products); Director (since 1987) of ABIOMED, Inc. * Trustee considered to be an "interested person" within the meaning of the Investment Company Act of 1940, as amended (the "1940 Act"), through position or affiliation with Hambrecht & Quist Capital Management LLC (the "Adviser"). ** Member of each Fund's Audit Committee. ^ Member of each Fund's Governance Committee. ~ Member of each Fund's Nominating Committee. # Member of each Fund's Valuation Committee. + Member of each Fund's Qualified Legal Compliance Committee. For the fiscal year ended September 30, 2004 each Fund paid its Independent Trustees an annual fee of $20,000. Each Fund currently pays each Independent Trustee $500 for each Board and Committee meeting attended in person and $250 for each Board and Committee meeting attended by telephone. For the fiscal year ended September 30, 2004 Independent Trustees of each Fund were paid $1,000 for each Board and Committee meeting attended in person and $500 for each Board and Committee meeting attended by telephone. Currently, the Chairman of the Board of Trustees, the Chairman of the Audit Committee and the Chairman of the Valuation Committee of each Fund receives an additional annual fee of $2,500. Currently, the Chairman of the Nominating Committee and the Chairman of the Governance Committee of each Fund receives an additional fee of $1,500. During the fiscal year ended September 30, 2004 the Chairman of each Committee received an additional fee of $1,500. Independent Trustees are also reimbursed for travel expenses incurred in connection with attending such meetings. For the fiscal year ended September 30, 2004, the Independent Trustees as a group received $169,608 from HQH and $167,490 from HQL for fees and reimbursed expenses. Neither of the Funds directly paid any additional compensation to the Trustees for the fiscal year ended September 30, 2004. Neither of the Funds directly paid any compensation to any officer in excess of $60,000 for the fiscal year ended September 30, 2004. Trustees and officers of the Funds who hold positions with the Adviser receive indirect compensation from the Funds in the form of the investment advisory fee paid to the Adviser. The following table sets forth information regarding compensation of Trustees by the Funds for the fiscal year ended September 30, 2004, but does not include expenses. COMPENSATION TABLE For the fiscal year ended September 30, 2004 NAME OF TRUSTEE FROM EACH FUND TOTAL COMPENSATION FROM BOTH FUNDS AND FUND COMPLEX Henri A. Termeer $23,500 $47,000
2006-05-08	Henri A. Termeer (60), Trustee of HQH (since 1989) and of HQL (since 1992); Chairman (since 1988), Chief Executive Officer (since 1985), and President (since 1983) of Genzyme Corporation... The members of each Fund's Governance Committee are Messrs. Lewin and Termeer and Dr. Mack... The members of each Fund's Nominating Committee are Messrs. Lewin and Termeer and Dr. Mack... Compensation Table: Henri A. Termeer $44,000 total compensation.

abrdn Healthcare Investors

abrdn Life Sciences Investors